Gilead Sciences: Make CURE for Hepatitis C affordable for the WORLD
Over 170 million+ people and their families are in desperate need of a cure that does not include interferon or ribavirin. Gilead Sciences apparently has at last achieved their goal of developing their own in-house cure for genotype 1 with sofosbuvir (Sovaldi) and ledipasvir (without ribavirin or interferon), and FDA approval should be forthcoming in October 2014. Gilead also now has proven success in Phase 2 trials with Sovaldi and GS-5816 (their in-house drug to replace daclatasvir) for genotype 1 through 6, a combination that thus far seems to have proven to be at least as equally as effective as the Gilead/Bristol trials and most likely will turn out to be a ‘one pill’ cure for ALL genotypes (without toxic interferon OR ribavirin).
Considering this has taken far longer than Gilead and the HCV community anticipated (well over two years), it is quite disheartening to realize now the HCV community has another ‘roadblock’ thrown between them and the possibility of being cured, and that is the $150,000+ price tag that is likely to be placed on this phenomenal game-changing cure.
Gilead Sciences, please reconsider the price you have placed on this cure and make it 'profitable for all'... a cure for a world epidemic as well as a great investment return for Gilead and their investors.
Today: Margaret is counting on you
Margaret Dudley needs your help with “Gilead Sciences: Make CURE for Hepatitis C affordable for the WORLD”. Join Margaret and 49,504 supporters today.